Neurologic and cognitive outcomes associated with the clinical use of xenon: a systematic review and meta-analysis of randomized-controlled trials
| Autor: | Lawrence S. C. Law, Tong J. Gan, Caspar Chi-Chung Chan, Elaine Ah-Gi Lo |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
inorganic chemicals
medicine.medical_specialty Xenon Anesthesia General law.invention 03 medical and health sciences 0302 clinical medicine Cognition Randomized controlled trial 030202 anesthesiology law Hypothermia Induced Anesthesiology Medicine Animals Humans cardiovascular diseases Asphyxia Asphyxia Neonatorum integumentary system business.industry Infant Newborn General Medicine Hypothermia Neurologic Effect Substance Withdrawal Syndrome Clinical trial Anesthesiology and Pain Medicine Anesthesia Meta-analysis medicine.symptom business Neurocognitive 030217 neurology & neurosurgery Out-of-Hospital Cardiac Arrest circulatory and respiratory physiology |
| Zdroj: | Canadian journal of anaesthesia = Journal canadien d'anesthesie. 65(9) |
| ISSN: | 1496-8975 |
| Popis: | Xenon has been shown to have positive neurologic effects in various pre-clinical models. This study systematically reviewed the randomized-controlled trials (RCTs) investigating neurologic and cognitive outcomes associated with the clinical use of xenon. We searched PubMed, CENTRAL, EMBASE, CINAHL, elibrary.ru (for Russian studies), Google Scholar (for Russian studies), and Wanfang (for Chinese studies) for appropriate RCTs comparing neurologic or cognitive outcomes after clinical use of xenon with control treatment or with other anesthetic agents. Seventeen RCTs met the inclusion criteria. Two studies investigated the effects of xenon plus therapeutic hypothermia to treat neonatal asphyxia or out-of-hospital cardiac arrest. Compared with therapeutic hypothermia alone, xenon and therapeutic hypothermia reduced cerebral white matter abnormalities after cardiac arrest but had no effect on neurocognitive outcome and mortality. Xenon had no added value when used to treat neonatal asphyxia. Thirteen RCTs compared neurocognitive effects of xenon with other anesthetic agents in surgical patients. While xenon may be associated with improved short-term (< three hours) cognitive outcome, no medium-term (six hours to three months) advantage was observed, and longer-term data are lacking. No differences in biochemical (S-100β, neuron-specific enolase) and neuropsychologic (attentional performance) outcomes were found with xenon compared with other anesthetic drugs. Finally, two studies suggest that brief, intermittent administration of sub-anesthetic doses of xenon to patients during the acute phase of substance withdrawal may improve neurocognitive outcomes. Despite promising pre-clinical results, the evidence for positive clinical neurologic and cognitive outcomes associated with xenon administration is modest. Nevertheless, there is some evidence to suggest that xenon may be associated with better neurologic outcomes compared with the standard of care therapy in certain specific clinical situations. More clinical trials are needed to determine any potential benefit linked to xenon administration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink